Shanghai Runshi Pharmaceutical Technology Co., Ltd
9
1
1
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 9 trials
100.0%
+13.5% vs industry average
11%
1 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade Meningioma
Role: lead
Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.
Role: lead
Relative Bioavailability and Food Effect of SYHA1813 Oral Solution in Healthy Participants
Role: lead
A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma
Role: lead
A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
Role: lead
A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma
Role: lead
A Study of Simmitinib Plus SG001 in Advanced Solid Tumors
Role: lead
A Phase I Trial of Simmitinib in Advanced Solid Tumors
Role: collaborator
A Study to Investigate the Safety of SYHA1815 in Subjects With Unresectable Locally Advanced or Metastatic Solid Tumors
Role: lead
All 9 trials loaded